Progetto Odin

21/05/2018

Corso FAD da 45 crediti ECM online fino al 31 dicembre 2018

06/09/2017

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study

Sorafenib is currently the only Food and Drug Administration–approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose...

06/09/2017

The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase [INNATE IMMUNITY AND INFLAMMATION]

Abstract

04/09/2017

Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution Within a Phase 2 Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer

Background: Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in EGFR inhibitor−treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational...

03/09/2017

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Supported by Cancer Research U.K. (CRUK_A12459), Medical Research Council (MRC_MC_UU_12023/25), Astellas Pharma, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.

02/09/2017

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non–germinal...

02/09/2017

Breast Mass Discovered in 49-Year-Old Patient https://buff.ly/2eMtOhT

01/09/2017

EHR Vendors Seek Clarity from CMS

Welcome to Practice Rounds, our weekly column exploring what’s being covered in the larger world of healthcare.